10-K: Amylyx Pivots Post-ALS Drug Withdrawal, Boosts Pipeline

Amylyx Pharmaceuticals reports a strategic shift following the withdrawal of its ALS drug, focusing on a pipeline of novel therapies for endocrine and neurodegenerative diseases, supported by significant capital raises.

Summary

• Voluntarily discontinued marketing and sales of RELYVRIO/ALBRIOZA (AMX0035) for ALS in the U.S. and Canada, resulting in no product revenue for the year ended December 31, 2025.
• Net loss significantly decreased to $144.7 million in 2025 from $301.7 million in 2024, primarily due to reduced operating expenses following a restructuring plan.
• Total operating expenses decreased by 62% to $153.3 million in 2025 from $402.1 million in 2024.
• Research and development (R&D) expenses decreased by 13% to $90.4 million in 2025, driven by a $35.0 million reduction in AMX0035 ALS spending, offset by a $21.3 million increase for avexitide's Phase 3 LUCIDITY trial.
• Selling, General and Administrative (SG&A) expenses decreased by 45% to $62.9 million in 2025, largely due to a 70% workforce reduction and decreased commercial activities.
• Cash, cash equivalents, and marketable securities totaled $317.0 million as of December 31, 2025, with an accumulated deficit of $751.4 million.
• Successfully raised approximately $256.2 million in net proceeds from two public offerings of common stock in January and September 2025.
• The Phase 3 LUCIDITY trial for avexitide in Post-Bariatric Hypoglycemia (PBH) has completed recruitment, with last patients expected to be dosed in Q1 2026 and topline data anticipated in Q3 2026, targeting a commercial launch in 2027 if approved.
• Positive Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome showed sustained improvement or stabilization in pancreatic beta cell function, glycemic control, and visual acuity.
• The Phase 1 LUMINA trial for AMX0114 in ALS dosed its first participant in April 2025, with initial safety data from Cohort 1 (n=12) showing general tolerability and no treatment-related serious adverse events by December 2025.
• AMX0318, a novel GLP-1 receptor antagonist for long-acting administration, was selected as a development candidate for PBH and other rare diseases in January 2026, with IND-enabling studies underway and an IND targeted for 2027.
• The ORION program for AMX0035 in PSP was discontinued in August 2025 due to lack of efficacy in the Phase 2b trial.
• The company is no longer an 'emerging growth company' and became a 'non-accelerated filer' as of December 31, 2025, leading to increased compliance requirements.
• Ongoing class action and derivative lawsuits related to previous commercial results and prospects for RELYVRIO are in mediation, with a status update expected by April 12, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with a neutral-to-slightly-negative sentiment. While the company successfully raised significant capital and is advancing its pipeline, the complete cessation of product revenue due to the withdrawal of its only commercial drug is a major negative. The reduced net loss is primarily a result of cost-cutting rather than new revenue generation, indicating a challenging transition period.

Positives

• Net loss significantly decreased to $144.7 million in 2025 from $301.7 million in 2024, indicating improved cost management.
• Total operating expenses decreased by 62% in 2025, reflecting successful implementation of a restructuring plan and reduced commercial activities.
• Successfully raised approximately $256.2 million in net proceeds from two public offerings in January and September 2025, strengthening the cash position.
• Cash, cash equivalents, and marketable securities of $317.0 million as of December 31, 2025, are projected to fund operations into 2028.
• Avexitide's Phase 3 LUCIDITY trial for PBH has completed recruitment, with positive Phase 2 data showing significant reduction in hypoglycemic events and good tolerability.
• AMX0035 in Wolfram syndrome demonstrated sustained improvements or stabilization in pancreatic function, glycemic control, and visual acuity in positive Week 48 Phase 2 HELIOS data.
• AMX0114 for ALS received Fast Track Designation and initial safety data from its Phase 1 LUMINA trial showed general tolerability with no serious adverse events.
• AMX0318 was selected as a new development candidate for PBH and other rare diseases, expanding the pipeline with a promising long-acting GLP-1 receptor antagonist.

Negatives

• Product revenue dropped to $0 in 2025 from $87.4 million in 2024 due to the voluntary discontinuation of RELYVRIO/ALBRIOZA for ALS.
• The Phase 3 PHOENIX trial for AMX0035 in ALS failed to meet its primary and secondary endpoints, leading to the withdrawal of the product from the market.
• The ORION program for AMX0035 in PSP was discontinued in August 2025 due to lack of efficacy.
• An accumulated deficit of $751.4 million as of December 31, 2025, highlights historical losses.
• Ongoing securities class action and derivative lawsuits allege materially false and misleading statements related to RELYVRIO's commercial prospects, posing potential liabilities and reputational harm.
• The company is no longer an 'emerging growth company' and became a 'non-accelerated filer', increasing compliance costs and management's time commitment to regulatory requirements.

Risks

• Inability to successfully complete late-stage trials, obtain regulatory approvals, and commercialize avexitide and/or AMX0035, or significant delays in doing so, could materially harm the business.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with potential for delays, denials, or limited approvals.
• Reliance on third parties for clinical trials and manufacturing increases risks of unsatisfactory performance, delays, or supply chain disruptions.
• Markets for product candidates may be smaller than expected, particularly for rare diseases, impacting potential revenue.
• Failure to expand sales, marketing, manufacturing, and distribution capabilities or secure third-party agreements could prevent generation of product revenue.
• Even if approved, product candidates may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• Product candidates may cause undesirable side effects or have other properties that delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-approval.
• Product liability lawsuits could divert resources, incur substantial liabilities, and limit commercialization.
• Ongoing healthcare legislative and regulatory reform measures, including drug pricing controls and changes to programs like Medicare and Medicaid, could adversely affect business and results of operations.
• Compliance with global privacy and data security requirements, including GDPR and evolving AI regulations, could result in additional costs and liabilities.
• Cyber-attacks, data breaches, or other failures in IT systems could result in information theft, data corruption, significant business disruption, and reputational damage.
• The ability to use net operating losses (NOLs) and research and development credits to offset future taxable income may be subject to limitations due to ownership changes or tax law changes.
• The price of common stock may be volatile due to various factors, including clinical trial results, regulatory decisions, and market conditions.
• Concentration of ownership among executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• Delaware law and company bylaws could make a merger, tender offer, or proxy contest difficult, potentially depressing the trading price of common stock.
• Failure to maintain proper and effective internal control over financial reporting could impair the ability to produce accurate and timely financial statements.
• Securities class action litigation could result in substantial costs and diversion of management's attention.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of common stock.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution and cause the stock price to fall.

Future Outlook

Amylyx Pharmaceuticals expects to continue incurring significant losses as it advances its clinical pipeline. The company anticipates topline data for the avexitide Phase 3 LUCIDITY trial in PBH in Q3 2026, with a potential commercial launch in 2027 if approved. Biomarker data for Cohort 1 of the AMX0114 LUMINA trial in ALS is expected in the first half of 2026. IND-enabling studies for AMX0318 are underway, targeting an IND in 2027. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2028, but acknowledges the need for additional funding if current operating plans are not achieved or if unforeseen costs arise.

Management Comments

• Our mission is to develop and advance novel therapies for communities with high unmet medical needs.
• We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality.
• We continue to expect to randomize and dose the last eligible patients in Q1 2026 with topline data expected in Q3 2026, and if approved, a commercial launch in 2027 for avexitide in PBH.
• Amylyx is committed to supporting medically and scientifically sound research, including externally-sponsored research conducted with an institution or organization.
• We continue to work with the FDA on a Phase 3 trial in Wolfram syndrome for AMX0035.
• Our human capital is integral to helping us achieve our goal to end the suffering caused by endocrine conditions and neurodegenerative diseases.

Industry Context

StockSavvy.ai notes that Amylyx Pharmaceuticals operates in the highly competitive biotechnology and pharmaceutical industries, characterized by rapid technological advancement and significant R&D investment. The company's strategic pivot away from ALS after the RELYVRIO/ALBRIOZA withdrawal highlights the inherent risks and high failure rates in neurodegenerative disease drug development. The focus on rare endocrine conditions like PBH and Wolfram syndrome, where unmet medical needs are high, aligns with a common industry strategy to leverage orphan drug designations and expedited review pathways. The increased demand for GLP-1 based therapeutics, as mentioned in the filing, indicates a dynamic and competitive landscape for avexitide and AMX0318. The ongoing legal and regulatory scrutiny on drug pricing and patient assistance programs, as well as the evolving AI regulatory environment, reflect broader industry challenges that could impact commercialization and operational costs for all players.

Comparison to Industry Standards

• The filing does not provide specific comparable company, project, or result data to assess performance against global industry benchmarks. It generally notes that many competitors have significantly greater financial resources and expertise in R&D, manufacturing, and marketing.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action lawsuit (Shih v. Amylyx Pharmaceuticals, Inc., et al.) was filed on February 9, 2024, alleging violations of Section 10(b) of the Exchange Act and Rule 10b-5, claiming materially false and misleading statements regarding RELYVRIO's commercial results and prospects. A motion to dismiss was denied on September 30, 2025, and a confidential mediation is scheduled for March 12, 2026.
• A derivative complaint (Jones v. Cohen, et al.) was filed on October 2, 2024, mirroring the Shih Complaint's allegations and adding claims for violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, insider trading, and unjust enrichment. This action was stayed on October 31, 2024.
• A second derivative complaint (Hassine v. Cohen, et al.) was filed on July 2, 2025, with similar allegations including violations of Sections 14(a), 10(b), and 21D of the Exchange Act, breach of fiduciary duty, and other common law claims. This complaint was consolidated with the Jones Derivative Complaint and its stay extended through April 30, 2026.

Stakeholder Impact

• Shareholders: Face significant dilution from recent equity offerings, potential stock price volatility due to pipeline developments and legal proceedings, and no anticipated cash dividends.
• Employees: Experienced a 70% workforce reduction as part of a restructuring plan, impacting job security but aiming for optimized resource allocation for remaining personnel.
• Patients: The discontinuation of RELYVRIO/ALBRIOZA for ALS removes an approved treatment option, but the company is actively developing new therapies for PBH, Wolfram syndrome, and ALS, offering future potential benefits.
• Suppliers: Engaged in negotiations to redefine relationships with third-party manufacturers following the RELYVRIO/ALBRIOZA discontinuation, potentially impacting future contracts and supply chain stability.
• Creditors: The company's strengthened cash position from capital raises provides greater financial stability, potentially reducing immediate concerns for creditors.

Next Steps

• Randomize and dose the last eligible patients in the Phase 3 LUCIDITY trial for avexitide in PBH in Q1 2026.
• Present Cohort 1 biomarker data from the Phase 1 LUMINA trial for AMX0114 in ALS in the first half of 2026.
• Engage in confidential mediation for the ongoing class action and derivative lawsuits, with a status update to the court by April 12, 2026.
• Continue working with the FDA on a Phase 3 trial for AMX0035 in Wolfram syndrome.
• Advance AMX0318 into IND-enabling studies, targeting an IND submission in 2027.
• Pursue regulatory approvals and potential commercialization for avexitide in PBH (targeting 2027 launch if approved) and other pipeline candidates.

Key Dates

Recommendation

Amylyx Pharmaceuticals is in a significant transition phase following the withdrawal of its only commercial product. While the company has successfully raised substantial capital and is advancing a diverse pipeline with promising early-stage data and designations, the lack of current product revenue and ongoing legal challenges create considerable uncertainty. The long development timelines for pharmaceutical products mean that commercial success is years away, and there are inherent risks of clinical trial failures. A 'hold' recommendation reflects the speculative nature of the investment, acknowledging the potential for future growth if the pipeline succeeds, but also the high risks and lack of immediate revenue generation.

Keywords

Amylyx Pharmaceuticals, Biotechnology, Neurodegenerative Diseases, Endocrine Conditions, Avexitide, Post-Bariatric Hypoglycemia, Congenital Hyperinsulinism, AMX0035, Wolfram Syndrome, AMX0114, Amyotrophic Lateral Sclerosis, ALS, AMX0318, GLP-1 Receptor Antagonist, Antisense Oligonucleotide, Clinical Trials, Regulatory Approval, SEC Filing, 10-K, Pharmaceutical Development, Orphan Drug, Breakthrough Therapy, Fast Track Designation, Capital Raise, Biopharma